Chief Executive Officer TJ Johnson to assume role of Executive Chairman at the end of first quarter 2019
John Lubniewski, President and Chief Operating Officer, appointed as successorContinue reading
Category Archives: AZBio News
Fighting Human Disease with Birth Control… for Mosquitoes
Researchers at the University of Arizona have discovered a protein that prevents mosquitoes from hatching, opening the possibility of developing new drugs that could act as birth control for mosquito populations.Continue reading
Flinn Foundation Awards Critical Path Institute and TGen North a New Grant to Develop and Pilot a System to Respond to Antimicrobial Resistance TUCSON, Ariz., January 8
Critical Path Institute (C-Path) and Flagstaff, Arizona-based TGen North — the Pathogen and Microbiome Division of the Translational Genomics Research Institute (TGen) — have received a Phase 1 Concept Validation grant from the Flinn Foundation, of $400,000 over 12 months, to develop and pilot a framework enabling the state institutions to be more responsive to antimicrobial resistance. Working as partners in this venture, C-Path and TGen, an affiliate of City of Hope, will solidify requirements among multiple stakeholders and develop an integrated deployment plan for a statewide Healthcare Associated Antimicrobial Resistant Microbe genomic surveillance system, dubbed Prevent HAARM.Continue reading
Essential nutrient may help fight Alzheimer’s across generations
In a new study, researchers at the Biodesign Institute explore a safe and simple treatment for one of the most devastating and perplexing afflictions: Alzheimer’s disease.Continue reading
Rowpar Pharmaceuticals CEO Shares Insights in Chief Executive Magazine
Jim Ratcliff shares what is like expanding into China during a Trade War.Continue reading
GT Medical Technologies Announces Publication of Data Showing Company’s Targeted Therapy is Effective for Treating Recurrences of Common Type of Brain Tumor
FDA-Cleared GammaTile Therapy Offers New Option for Patients with Recurrent Meningiomas
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
- Highly Complementary Portfolios with Leading Franchises in Oncology, Immunology and Inflammation and Cardiovascular Disease
- Significantly Expands Phase III Assets with Six Expected Near-Term Product Launches, Representing Greater Than $15 Billion in Revenue Potential
- Registrational Trial Opportunities and Early-Stage Pipeline Position Combined Company for Sustained Leadership Underpinned by Cutting-Edge Technologies and Discovery Platforms
- Strong Combined Cash Flows, Enhanced Margins and EPS Accretion of Greater Than 40% in First Full Year
- Approximately $2.5 Billion of Expected Run-Rate Cost Synergies to Be Achieved by 2022
Xcellerate Biomedical Technologies Announces Half a Million Dollar Raise
Xcellerate Biomedical Technologies, a new company based in Phoenix, AZ, has announced its second round capital raise of $500k for its first line of products, BioXcellerator™ – a medical strength line of formulations sold exclusively through top dermatologists, plastic surgeons, orthopedists and OB/GYN doctors. Continue reading